Cover Image

市場進入的課題:腎細胞癌 (美國)

Market Access Impact: Renal Cell Carcinoma (US)

出版商 FirstWord 商品編碼 358502
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:腎細胞癌 (美國) Market Access Impact: Renal Cell Carcinoma (US)
出版日期: 2016年05月01日 內容資訊: 英文



  • 各種障礙對打入市場的影響
    • 醫生最大量開處方的品牌為何?
    • 受各種障礙影響的處方箋數為何?
    • 哪個障礙最影響大?
  • 障礙對各品牌的影響
    • 醫生對各品牌的處方數為何?不打算再開處方的數為何?
    • 醫生不開處方的理由為何?替代其開處方的藥物為何?
    • 被競爭品牌奪走的佔有率有多少?


  • Afinitor
  • Avastin
  • Inlyta
  • Nexavar
  • Opdivo
  • Proleukin
  • Sutent
  • Torisel
  • Votrient
Product Code: 596200687

Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them?

We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists can't prescribe freely. The result: 6 of those brands actually saw a net gain.

Is your brand one of them, or one of the 3 that are losing out?

You'll learn how market barriers affect share for 9 major treatments from Bayer/Amgen, BMS, Genentech, Pfizer, and Prometheus.

Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Get Answers to Key Questions about RCC Drug Brands

  • Afinitor (everolimus; Novartis): Does Afinitor lose more share to Avastin or Sutent?
  • Avastin (bevacizumab; Genentech): Are doctors who don't prescribe either brand more likely to consider Avastin or Opdivo?
  • Inlyta (axitinib; Pfizer): Which two barriers contribute equally to Inlyta's small net share loss?
  • Nexavar (sorafenib; Bayer/Amgen): Does Nexavar gain more share when other brands are too expensive or when they're not reimbursable?
  • Opdivo (nivolumab; BMS): Opdivo and Sutent are prescribed equally. Which one has the clear market share advantage?
  • Proleukin (aldesleukin; Prometheus): Which three barriers do more doctors experience with Proleukin than any other brand?
  • Sutent (sunitinib; Pfizer): Which two brands would threaten Sutent if market barriers were eliminated?
  • Torisel (temsirolimus; Pfizer): Torisel sees a net gain against all but three brands. Which three?
  • Votrient (pazopanib; Novartis): Only two market barriers contribute to Votrient's net share gain. What are they?

Top Takeaways

  • Most brands benefit from barriers: Six of the nine surveyed brands saw a net share gain due to barriers. Only three saw a net loss.
  • Eliminating barriers would shake up the market: Especially the top of the market, where one middle-ranked brand would move into the top 3, pushing a leading brand out.
  • Barrier effect is brand-specific: Each barrier tends to affect one or two brands far more than the others.
  • All brands are heavily prescribed: Although a majority of doctors prescribe all but one of the surveyed brands, two brands are more prescribed than any of the others.
  • Clear market leaders: Two brands-one of them among the most prescribed-have a clear market share lead.
  • Brand perception is good: With a few exceptions, most doctors are willing to consider prescribing the brands they don't currently prescribe.
  • Cost barriers have the greatest impact: barriers related to pricing and formulary availability (which is often related) affect more prescriptions than any others.
  • Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 7 of the surveyed brands, and see the third biggest net share gain.

Exploring Market Access Issues

Market Access Impact: psoriasis explores key issues affecting RCC drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 medical oncologists in the US, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.

Back to Top